Durvalumab as Consolidation for Patients LS-SCLC
NCT07055581
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Small Cell Lung Cancer Limited Stage
Interventions
DRUG:
Induction Durvalumab +etoposide/platinum +Radiochemotherapy+ durvalumab maintenance
Sponsor
Qian Chu